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A B S T R A C T
IMPLICATIONS ANDPurpose: The purpose of the study was to describe the patterns of use of universally recommended
adolescent vaccines in the United States.
Methods: We identified 11-year-olds using the MarketScan insurance claims database (2009e
2014). Human papillomavirus (HPV), tetanus-diphtheria-acellular pertussis (Tdap), and menin-
gococcal (MenACWY) vaccination claims were identified using diagnosis and procedure codes.
Generalized linear models estimated vaccination incidence rates and correlates of adolescent
vaccination and timely vaccination.
Results: Among 1,691,223 adolescents, receipt of Tdap (52.1%) and MenACWY (45.8%) vaccinations
exceeded receipt of HPV vaccination (18.4%). While both sexes had similar Tdap and MenACWY
vaccination proportions, girls received HPV vaccination more frequently than boys (21.9% vs. 15.1%).
Adolescents received HPV vaccination later (mean age: 11.8 years) than Tdap or MenACWY
vaccination (mean age: 11.2 years for both). Half of vaccinated adolescents received Tdap and
MenACWY vaccination only; however, coadministration with HPV vaccine increased with birth
cohort. Western adolescents had the highest incidence rates of HPV vaccination, and Southern
adolescents had the lowest. Rural adolescents were less likely than urban adolescents to receive
each vaccination except in the Northeast, where they were more likely to receive HPV vaccination
(incidence rate ratio: 1.09, 95% confidence interval: 1.2005e1.13). Timely HPV vaccination was
associated with female sex, urbanicity, Western residence, and later birth cohort.
Conclusions: HPV vaccination occurred later than Tdap or MenACWY vaccination and was less
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This study assessed vac-
cine coadministration and
the dual influence of ge-
ography and urbanicity on
adolescent vaccination
using insurance claims.
Access to and demand for
vaccines should be
improved in rural areas,
and providers should
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lomavirus vaccination and
vaccine coadministration
to all eligible adolescents.ed research award from Pfizer for an
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N.A. Vielot et al. / Journal of Adolescent Health 61 (2017) 281e287282cohorts were more likely to receive timely HPV vaccination. Vaccine coadministration increased
over time and may encourage timely and complete vaccination coverage.
 2017 Society for Adolescent Health and Medicine. All rights reserved.The Centers for Disease Control and Prevention’s Advisory
Committee on Immunization Practices (ACIP) recommended
routine meningococcal conjugate (MenACWY) and tetanus-
diphtheria-acellular pertussis (Tdap) vaccination for adoles-
cents at age 11 years, in 2005 and 2006, respectively [1e3]. ACIP
subsequently recommended routine human papillomavirus
(HPV) vaccination for females aged 11e12 years on June 29,
2006, and for males aged 11e12 years on October 21, 2009 [4e6].
Phase III clinical trials of the prophylactic quadrivalent (4vHPV)
and bivalent (2vHPV) HPV vaccines demonstrated over 90%
efficacy against high-grade or greater cervical intraepithelial
neoplasia (CIN-2þ) associated with high-risk HPV (hrHPV) types
16 and 18 [7,8].
Despite ACIP’s recommendations and strong evidence for the
safety and efficacy of HPV vaccines, receipt of at least one dose of
HPV vaccine (56.1%) among boys and girls aged 13e17 years lags
behind receipt of Tdap (86.4%) or MenACWY (81.3%) vaccines in
the United States, according to the 2016 nationally representative
National Immunization Survey-Teen (NIS-Teen) [9].
In the NIS-Teen surveys, parents report their children’s
vaccination status and their children’s vaccination providers are
contacted to confirm vaccination status. However, vaccination
status might be misclassified if parents do not accurately recall
their children’s vaccination providers, or if providers have inac-
curate vaccination records [10]. Furthermore, the random digit
dialing sampling strategy used for NIS-Teen results in low
response rates, and the sample may not be generalizable to the
U.S. population. Alternatively, insurance claims provide accurate
data on adolescent vaccination for millions of individuals, elim-
inating the need to review medical records and reducing recall
and information biases. Furthermore, insurance claims also allow
monitoring of coadministration of vaccines on the same service
date and trends over time in uptake of different vaccine combi-
nations, which have only been recently reported in two studies
using NIS-Teen data [11,12].
Here, we present data from employer-sponsored insurance
claims to describe patterns of use of HPV, Tdap, and MenACWY
vaccination among vaccine-eligible girls and boys in the United
States. Results from this study will identify gaps in vaccination
coverage and can inform targeted adolescent vaccination
promotion strategies.
Methods
Study population
The MarketScan Commercial Claims and Encounters database
captures patient-level medical claims provided by over 300 large
employers in all 50 states, the District of Columbia, and Puerto
Rico, including over 170 million unique enrollees since 1995 [13].
MarketScan provides patient demographic data, type and duration
of health plan enrollment, claims for medical diagnoses and pro-
cedures using International Classification of DiseaseseNinth
Revision (ICD-9) and Current Procedural Terminology (CPT) codes,
respectively, and dates of medical services. We obtained Market-
Scan data between 2000 and 2014 from Truven Health Analytics.The study period began in October 21, 2009dwhen ACIP
supported HPV vaccination for boysdmarking the first oppor-
tunity for all eligible adolescents to receive all three recom-
mended vaccines. We included girls and boys who (1) turned
11 years of age between 2009 and 2014; (2) had no prior history
of adolescent vaccination; and (3) had at least 1 year of contin-
uous insurance plan enrollment before the start of follow-up.
Data analysis
We began observing adolescents from their 11th birthdays,
when they became eligible for adolescent vaccination according
to the ACIP recommendations. Because date of birth is protected
health information, we searched monthly insurance enrollment
files to identify the month inwhich the adolescent’s age changed
and then set the date of birth to the last day of that month. We
followed adolescents from their estimated 11th birthdays (time
0) until vaccination, disenrollment, or the end of the study period
on December 31, 2014.
We searched outpatient records for the first billed claim for
2vHPV (CPT code 90650) or 4vHPV (CPT code 90649), Tdap (CPT
code 90715, ICD-9 code 9939), and MenACWY (CPT code 90734).
We excluded Tdap claims related to injuries or accidents (ICD-9
codes 037.X, 87Xe91X, V01eV02, all E codes) or receipt of
antenatal care (ICD-9 codes V22.XeV39.X). While the HPV
vaccination series includes multiple doses and MenACWY vac-
cine requires a booster, we only identified the first dose of each
vaccine, as limited follow-up might prevent us from observing
subsequent doses. Descriptive statistics summarized service-
related characteristics at the time of vaccination, and the
combinations of vaccines received by adolescents, including
coadministered vaccines.
For each vaccine, we estimated time to vaccination as the
difference between time 0 and the date of the first vaccination
claim. We estimated total follow-up time as the difference
between time 0 and the date of service for adolescents who
received vaccination; or the difference between time 0 and the
date of disenrollment or the end of the study period for adoles-
cents who did not receive vaccination. We used generalized
estimating equations with a Poisson distribution and a robust
variance estimator to estimate vaccination incidence rates (IRs)
per 10,000 person-months of observation, incidence rate ratios
(IRRs) and 95% confidence intervals (CIs) for correlates of vacci-
nation, and IRs of vaccine coadministration over time. IRs and
cumulative incidence were stratified by covariates of interest,
including sex; region (Northeast, North Central, South, West, per
the U.S. Census Bureau [14]); urbanicity, as defined by urban
residence (metropolitan statistical area with population
50,000) or rural residence (micropolitan statistical area with
population <50,000); receipt of primary care in the year before
observation; and insurance plan type. We also plotted the
cumulative incidence of receiving the first dose of HPV vaccine at
age 11 or 12 years (i.e., timely HPV vaccination), stratified by sex,
urbanicity, region, and birth cohort.
As many as 18 states had offered at least one adolescent
vaccine free of charge, regardless of income level, since 2006
Table 1
Incidence of HPV, Tdap, and MenACWY vaccination among adolescents in the MarketScan database, 2009e2014a
Incidence of vaccination Overall (n ¼ 1,691,223) Girls (n ¼ 822,554) Boys (n ¼ 868,669)
Median duration (IQR) of follow-up, months 16.1 (7.1e31.2) 16.1 (7.1e31.2) 16.1 (7.1e31.2)
Cumulative incidence (incidence proportion) of adolescent vaccination
Any vaccination 948,995 (56.1%) 467,355 (56.8%) 481,640 (55.5%)
HPV vaccination 311,110 (18.4%) 180,373 (21.9%) 130,737 (15.1%)
Tdap vaccination 880,586 (52.1%) 431,814 (52.5%) 448,772 (51.7%)
MenACWY vaccination 774,132 (45.8%) 378,377 (46.0%) 395,755 (45.6%)
Overall (n ¼ 948,995) Girls (n ¼ 467,355) Boys (n ¼ 481,640)
Mean age (SD) at first adolescent vaccination 11.5 (.8) 11.5 (.8) 11.5 (.8)
HPV vaccination (n ¼ 311,110) 11.8 (1.0) 11.7 (1.0) 12.0 (1.1)
Tdap vaccination (n ¼ 880,586) 11.2 (.5) 11.2 (.5) 11.3 (.5)
MenACWY vaccination (n ¼ 774,132) 11.2 (.6) 11.3 (.6) 11.3 (.6)
IQR¼ interquartile range; HPV¼ human papillomavirus vaccine; MenACWY¼meningococcal conjugate vaccine; Tdap¼ tetanus-diphtheria-acellular pertussis vaccine;
SD ¼ standard deviation.
a Eligible 11-year-olds are those who are continuously enrolled in an insurance plan as of the midpoint of their 11th year and had not previously received HPV/Tdap/
MenACWY vaccines. The Advisory Committee on Immunization Practices recommends all three vaccines beginning at age 11 years.
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Nevada, New Hampshire, New Mexico, North Carolina, North
Dakota, Oregon, Rhode Island, South Dakota, Vermont, Wash-
ington, Wisconsin, and Wyoming) [15]. Adolescents from these
states may have received vaccination without filing insurance
claims, and thus, their vaccination status would not be ascer-
tained from MarketScan data. We conducted a sensitivity
analysis excluding these states to assess potential bias due to
underascertainment of vaccination status.
Analyses were performed in SAS 9.3 (Cary, NC). Proportional
Venn diagrams were created using the eulerAPE application
(Canterbury, UK) [16]. The University of North Carolina Office of
Human Research Ethics approved this study.
Results
The analytic cohort included 1,691,223 adolescents: 822,544
girls and 868,669 boys. The median duration of follow-up was
16 months (interquartile range, 7e31 months) (Table 1). We
observed at least one adolescent vaccination for 948,995
adolescents (56.1%) during the observation period. Of the 922,137
adolescents who were enrolled until the end of the study period
on December 31, 2014, 66.7% of them received any adolescent
vaccination; of the 769,086 adolescents who disenrolled during
follow-up, 43.4% of them received any adolescent vaccination.
Similar percentages of girls and boys received Tdap and Men-
ACWY; however, the proportion of adolescents receiving HPV
vaccinationwas higher in girls than boys (21.9% vs.15.1%; Table 1).
Mean age at receipt of the first dose of HPV vaccine (11.8 years)
was higher than that for Tdap and MenACWY (11.2 years for
both), and girls received HPV vaccination relatively earlier than
boys (mean age 11.7 years vs.12.0 years). Among adolescents who
received any vaccination, over 96% received Tdap or MenACWY
vaccinationwithin the ACIP-recommended age range. In contrast,
81% of girls and 72% of boys received HPV vaccination within the
ACIP-recommended age range (Table A1).
One quarter of adolescents who received any vaccination
received all three recommended vaccines; 50.6% received Tdap
and MenACWY only (Figure 1). For adolescents who received
Tdap and MenACWY vaccination only, 92.3% received both
concomitantly at their initial adolescent vaccination visit. How-
ever, only 24.1% of adolescents who received all three vaccina-
tions received them concomitantly at the initial vaccination visit.
Coadministration IRs of Tdap þ MenACWY were higher thanthose for HPVþ TdapþMenACWY in each birth cohort, although
IRs of both coadministration combinations increased steadily
with each successive birth cohort (Figure A1).
The IRs of HPV, Tdap, and MenACWY vaccination were lower
in rural adolescents than urban adolescents (Table 2). The high-
est HPV vaccination IRs were observed in theWest (117.2, 95% CI:
116.3e118.0), and the lowest HPV vaccination IRs were observed
in the South (91.3, 95% CI: 90.8e91.9). The West region had the
lowest IRs of Tdap (IR: 404.7, 95% CI: 404.2e407.1) and Men-
ACWY (IR: 299.7, 95% CI: 297.8e301.5) vaccination. The IRs of all
vaccinations were lowest among adolescents with comprehen-
sive insurance plans, and adolescents who had received any
primary care in the year before the start of observation had
higher IRs of all vaccinations than those without a primary care
visit (Table 2).
Overall, rural adolescents had lower IRs than urban adoles-
cents of HPV (IRR: .76, 95% CI: .75e.77), Tdap (IRR: .58, 95% CI:
.57e.58), and MenACWY vaccination (IRR: .53, 95% CI: .53e.54)
(Table 3). Rural adolescents in the North Central, South, andWest
regions were less likely than urban adolescents to receive HPV
vaccination, whereas adolescents in the Northeast were more
likely to receive HPV vaccination (IRR: 1.09, 95% CI: 1.05e1.13)
(Table 3).
The cumulative incidence of timely HPV vaccination differed
across subgroups (Figure 2). Timely HPV vaccination was more
frequent in girls versus boys, regardless of the time since start of
follow-up. Adolescents residing in urban areas had a higher
incidence of timely vaccination than adolescents residing in rural
areas, and adolescents in theWest had higher incidence of timely
HPV vaccination than adolescents in the Northeast, North Cen-
tral, or South regions. With more recent birth cohort, the cu-
mulative incidence of timely HPV vaccination increased
incrementally (Figure 2).
After repeating these analyses excluding the 18 states that
offered free universal adolescent vaccine coverage, we observed
comparable vaccination proportions, vaccination combinations,
and stratified IRs of vaccination. None of the interpretations of
our findings were changed.
Discussion
Among 1.7 million vaccine-eligible adolescents with
employer-sponsored insurance in the United States, we observed
relatively lower IRs of HPV vaccination than Tdap or MenACWY
Figure 1. Incidence proportions of HPV, Tdap, and MenACWY combinations received (n ¼ 948,995). Combinations of vaccinations received among adolescents who
received any vaccination during follow-up. The combinations represent all vaccinations received during follow-up, regardless of receipt in the same or separate clinic visits.
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more often delayed beyond the 11- to 12-year age range uni-
versally recommended by ACIP compared with Tdap and Men-
ACWY vaccination. For all three recommended vaccines, rural
adolescent residents were consistently less likely to be vacci-
nated than their urban counterparts in all geographical regions
(South, Northeast, and West) except in the Northeast. Our data
also suggest birth cohort effects for coadministration of all
three recommended vaccines, suggesting increased use of
coadministration over time and increased integration of HPV into
the adolescent vaccination package over time.
Similar to other studies, our data indicate that adolescents
have frequent missed opportunities for HPV vaccination, namely
clinic visits in which Tdap and/or MenACWY vaccines were
administered [17]. In our sample, although over half of adoles-
cents had initiated adolescent vaccination, most adolescents had
not received HPV vaccination by the end of follow-up. Of those
who did, 23% received HPV vaccination outside of the ACIP-
recommended age range (Table A1). The National Health and
Nutrition Examination Survey found that 43% of adolescents
initiated HPV vaccination after or in the same year as sexual
debut, increasing their risk for prevaccination HPV exposure [18].
While ACIP recommends catch-up vaccination for adolescents
older than 12 years, HPV vaccine effectiveness is highest before
sexual debut [19]. Among 1,139 inner-city adolescent women inNew York City, receiving HPV vaccination after age 15 years was
associated with an increased hazard of high-grade cervical le-
sions relative to receiving vaccination before age 15 years [20].
Thus, it is critical that providers recommend HPV vaccination in
boys and girls at the earliest opportunity, including sick visits and
visits for other adolescent vaccinations.
Our study found that rural adolescents in the Northeast had
higher IRs of HPV vaccination than their urban counterparts,
although rural adolescents overall had lower IRs of vaccination
with all three adolescent vaccines. The increase in HPV vacci-
nation that we observed in rural, Northeastern adolescents could
simply be a function of the smaller size of this region and fewer
access barriers to vaccination for rural adolescents. Future
research should identify specific barriers to vaccination in rural
areas, besides economic factors, and differences in these factors
by region. Provider factors in rural areas may influence whether
they recommend HPV vaccination for their adolescent patients
[21]. A study comparing HPV vaccination recommendation
behavior among 334 pediatricians in Appalachian and non-
Appalachian counties of Kentucky and West Virginia found that
Appalachian pediatricians were less likely to recommend HPV
vaccination to their adolescent patients [22]. Furthermore, rural
adolescents are more likely to receive care from a family physi-
cian rather than a pediatrician and thus may be less likely to
receive recommendations for HPV vaccination [23]. All provider
Table 2
Incidence rates per 10,000 person-months of HPV, Tdap, and MenACWY vaccination among adolescents by selected characteristics, 2009e2014 (n ¼ 1,691,223)
HPV Tdap MenACWY
IR (95% CI) IR (95% CI) IR (95% CI)
Metropolitan statistical area
Urban (n ¼ 1,423,989) 103.9 (103.5e104.2) 527.5 (526.0e528.9) 414.9 (413.7e416.1)
Rural (n ¼ 231,792) 78.8 (77.9e79.6) 304.5 (302.3e306.8) 221.8 (220.0e223.6)
Missing (n ¼ 35,442)
Region of residence
Northeast (n ¼ 247,991) 104.3 (103.4e105.2) 685.3 (680.3e690.3) 526.8 (532.1e530.6)
North Central (n ¼ 426,605) 99.3 (98.7e100.0) 542.8 (540.1e545.4) 417.2 (415.0e419.3)
South (n ¼ 637,009) 91.3 (90.8e91.8) 446.9 (445.1e448.7) 364.1 (362.5e365.7)
West (n ¼ 343,161) 117.2 (116.3e118.0) 404.7 (402.4e407.1) 299.7 (297.8e301.5)
Missing (n ¼ 36,457)
Insurance plan type
Preferred provider plan (n ¼ 1,043,991) 96.8 (96.4e97.3) 484.5 (482.9e486.1) 373.4 (372.2e374.7)
Comprehensive (n ¼ 18,649) 81.5 (78.9e84.3) 423.4 (412.5e434.6) 330.5 (321.8e339.4)
Managed care plan (n ¼ 332,193) 109.5 (108.8e110.3) 458.8 (456.1e461.5) 364.6 (362.4e366.8)
High deductible plan (n ¼ 244,662) 105.5 (104.6e106.3) 575.2 (571.5e579.0) 454.0 (451.0e457.0)
Missing (n ¼ 51,728)
Received primary care in the past year
No (n ¼ 1,493,373) 98.4 (98.1e98.8) 472.6 (471.4e473.9) 368.0 (366.9e369.0)
Yes (n ¼ 197,850) 119.8 (118.7e120.9) 676.3 (671.4e681.2) 533.9 (530.0e537.9)
CI ¼ confidence interval; HPV ¼ human papillomavirus vaccine; IR ¼ incidence rate; MenACWY ¼ meningococcal conjugate vaccine; Tdap ¼ tetanus-diphtheria-
acellular pertussis vaccine.
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developed by the Centers for Disease Control and Prevention to
recommend HPV vaccination to eligible adolescents. In a national
sample, Centers for Disease Control and Prevention messages
pertaining to the high prevalence of HPV infection, the impor-
tance of HPV vaccination for cancer prevention, and the efficacy
of HPV vaccination were acceptable to caregivers who were
reticent to vaccinate their adolescents [24].
Studies of caregivers’ attitudes toward HPV vaccination reveal
concerns about vaccine safety and effectiveness, low perception
of risk for HPV infection, and unwillingness to vaccinate adoles-
cents who presumably are not sexually active against a sexually
transmitted infection [25e27]. Adolescent health care providers
should actively communicate the evidence-based vaccination
benefits to caregivers, particularly in regions that have low HPV
vaccination coverage. In addition, enhancing health care practices
to facilitate vaccination can effectively increase HPV vaccination
initiation. In a cluster randomized trial in Pennsylvania pediatricTable 3
Incidence rate ratios for the association of urbanicity with HPV, Tdap, and MenACWY
HPV
IRR (95% CI)
All Regions (n ¼ 1,655,781)a
Urban 1.0 (ref)
Rural .76 (.75e.77)
Northeast (n ¼ 247,991)
Urban 1.0 (ref)
Rural 1.09 (1.05e1.13)
North Central (n ¼ 426,605)
Urban 1.0 (ref)
Rural .76 (.74e.77)
South (n ¼ 637,009)
Urban 1.0 (ref)
Rural .77 (.75e.78)
West (n ¼ 343,161)
Urban 1.0 (ref)
Rural .68 (.66e.71)
CI ¼ confidence interval; HPV ¼ human papillomavirus vaccine; IRR ¼ incidence rate r
acellular pertussis vaccine.
a 35,442 observations missing region status.and family medicine practices, the 4 Pillars Practice Trans-
formation Program, which promotes strategies such as patient
notification for vaccination and establishing HPV vaccination
champions in practices, was associated with greater increases in
HPV vaccination initiation compared with control practices [28].
Our primary limitation is the short follow-up time (median
16 months) to observe vaccination receipt, preventing us from
observing vaccination events that occurred after the end of
follow-up. As a result, our longitudinal study yielded smaller
vaccination incidence proportions than the vaccination coverage
rates reported by NIS-Teen, which used cross-sectional methods.
We were also limited to reporting only the first instance of HPV
and MenACWY vaccination to avoid drawing invalid conclusions
about the completion of these vaccination series. Second, there is
a chance of misclassification of vaccination status due to the use
of incorrect or alternate CPT or ICD-9 codes. We attempted to use
all relevant vaccination codes to minimize underascertainment of
vaccination receipt. However, MarketScan is not able to track allvaccination among eligible adolescents, stratified by region, 2009e2014
Tdap Men
IRR (95% CI) IRR (95% CI)
1.0 (ref) 1.0 (ref)
.58 (.57e.58) .53 (.53e.54)
1.0 (ref) 1.0 (ref)
.86 (.84e.88) .79 (.77e.82)
1.0 (ref) 1.0 (ref)
.50 (.49e.50) .46 (.46e.47)
1.0 (ref) 1.0 (ref)
.60 (.59e.60) .55 (.54e.56)
1.0 (ref) 1.0 (ref)
.55 (.54e.57) .46 (.45e.47)
atio; MenACWY ¼meningococcal conjugate vaccine; Tdap ¼ tetanus-diphtheria-
Figure 2. Cumulative incidence of timely HPV vaccination at age 11e12 years, by selected characteristics (n ¼ 1,691,223). Cumulative incidence curves for HPV
vaccination within the ACIP-recommended age range, showing differences in timely HPV vaccination, stratified by sex, urbanicity, region, and birth cohort.
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torical vaccination data for adolescents who changed insurance
might not be recognized. Third, because MarketScan represents
employer-sponsored insurance claims, our results may not be
generalizable toMedicaid and uninsured populations.We also are
unaware of howmanyMarketScan enrollees are Medicaid eligible
and might receive vaccination through channels that bill
Medicaid. However, we observed comparable vaccination pro-
portions and IRs after excluding states that offer free adolescent
vaccination, indicating that vaccination patterns are similar be-
tween adolescents with access to free vaccination and those
without. These analyses should be replicated in Medicaid data to
identify any disparities in vaccination patterns by insurance
source. The Affordable Care Act of 2010 guarantees that immu-
nizations are covered under all insurance plans [29]. Deductible
and other payment factors or provider selection factors, however,
may influence vaccination decisions. Future research should
assess the impacts of insurance coverage on adolescent vaccina-
tion. Finally, MarketScan lacks data on race and ethnicity, and we
cannot know the degree to which regional differences are influ-
enced by racial or ethnic variation in vaccination patterns.
The strengths of this analysis include a large sample of
adolescents in the United States and minimally biased docu-
mentation of vaccine receipt. In identifying nearly one million
vaccinated adolescents, we had sufficient power to identify cor-
relates of vaccination status with precision. Using procedure and
diagnosis codes from a large insurance claims database, we
estimated vaccination IRs beginning at the age recommended by
ACIP, allowing us to assess vaccination timeliness. We also maderobust estimates of vaccination incidence using methods that
account for differential follow-up times and censoring.
Recent changes to HPV vaccine availability and recommen-
dations may improve the uptake and impact of this vaccine.
A nine-valent vaccine (9vHPV) preventing the seven hrHPV types
most highly associated with CIN-2þ was approved by the U.S.
Food and Drug Administration in December 2014 and recom-
mended by ACIP for 11- and 12-year-olds in March 2015 [30,31].
This broad-coverage prophylactic vaccine promises to prevent
even more cases of CIN-2þ attributed to hrHPV types when
administered in a timely fashion. Future research can use Mar-
ketScan to monitor patterns of use of 9vHPV relative to 4vHPV
and 2vHPV, and its concomitant usewith Tdap andMenACWY. In
addition, following a review of immunogenicity and effectiveness
data, ACIP recommended in December 2016 that the HPV vacci-
nation series be reduced to two doses from three for adolescents
who vaccinate before age 15 years [32]. This new recommendation
may increase the acceptability of HPV vaccination due to a lower
burden of clinic visits; reduce safety concerns associated with
multiple doses of HPV vaccination; and simplify medical record
keeping and vaccination status monitoring.
Offering HPV, Tdap, and MenACWY as a comprehensive
adolescent vaccination package could increase HPV vaccination
to the same levels as Tdap and MenACWY. Safety and immuno-
genicity research supports coadministration of HPV, Tdap, and
MenACWY, and ACIP recommends coadministration of all three
vaccines at age 11 or 12 years [33,34]. HPV vaccination trends are
encouraging, as indicated by more timely HPV vaccination and
coadministration of all three recommended adolescent vaccines
N.A. Vielot et al. / Journal of Adolescent Health 61 (2017) 281e287 287among adolescents born more recently. However, adherence to
ACIP recommendations for HPV vaccination timing and HPV
vaccination in boys remains particularly suboptimal. Providers
can educate caregivers about the benefits of vaccination,
including information about recent disease outbreaks due to
poor vaccine coverage. Providers should also avoid creating
exceptions for HPV vaccination, stressing that all adolescent
vaccines are safe, effective, and appropriate for 11- and 12-year-
old girls and boys, unless contraindicated. Demand for and access
to HPV vaccination for adolescents in rural areas must be
improved, and early and concomitant vaccination can reduce the
burden of adolescent preventive care in harder-to-reach areas.
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